Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 2 N=76 A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
Meibomian Gland Dysfunction · Dry Eye
Primary: Meibomian Glands Yielding Liquid Secretion (MGYLS) — -0.7; 3.41; 3.07; 1.88 Number of Open Glands
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
Phase 3 N=40 A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
Dry Eye Syndromes
Primary: Tear Evaporation Rate — 77.7; 67; 75.3 g/m^2*h
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
Phase 3 N=287 Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Dry Eye
Primary: Mean Change in Fluorescein Staining Score From Baseline — -2.12; -2.08 points
Phase 3 N=18 Dry Eye Assessment and Management: Feasibility Study
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change on Ocular Surface Disease Index (OSDI)
Phase 2 N=150 IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Schirmer's — 1.3; 2.1; 0.9 mm
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
Phase 2 N=305 Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — -25.66; -25.14; -29.95; -24.81 units on a scale
Phase 2 N=153 Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — 58.95; 57.21; -18.80; -16.60 units on a scale
Phase 3 N=81 A Study Designed to Evaluate Tear Production
Dry Eye Disease
Primary: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — 519.65 micrometers — p=<0.0001
N/A N=161 Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Impact of Dry Eye on Everyday Life - Symptom Bother (IDEEL-SB) Questionnaire Score at Day 30 — -16.95 score on a scale — p=<.0001
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
Phase 2 N=102 A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Dry Eye
Primary: Inferior Corneal Staining Score — -0.08; -0.03 units on a scale
Phase 3 N=80 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Percentage Change From Baseline in Goblet Cell Density at Day 90 for 0.003% AR-15512 — 94.61 percent change — p=0.1765
N/A N=40 Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline in Foreign Body Sensation, Burning/Stinging, Itching, Pain, Stick Feeling, Blurred Vision, Photophobia and Total Ocular Tolerability Score (VAS)…
Phase 2 N=138 Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
Phase 3 N=757 A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease — 0; 0 Participants
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
N/A N=20 Acute Comfort of Lubricant Eye Drop FID 111421
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.7; 1.3 Units on a scale
Phase 3 N=40 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Dry Eye Syndrome
Primary: Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score — -6.8 score on a scale
Phase 2 N=300 A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Syndrome
Primary: Efficacy of ADX-102 on the Ora Calibra® Discomfort & 4-Symptom Questionnaire for Dryness. — -0.7; -0.5; -0.4 units on a scale
Phase 2 N=158 A Clinical Trial to Assess Subjects With Dry Eye Disease.
Dry Eye
Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.066; 0.183 units on a scale